DNA nanomachine blood test for pancreatic cancer diagnosis
Part of Cancer, Digestive system clinical trials.
This trial uses a tiny DNA-based machine to detect tumor signals in your blood. It aims to improve how doctors diagnose pancreatic cancer, especially at an early stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic ductal adenocarcinoma (a type of pancreatic cancer) confirmed by a biopsy.
- You have not yet started any cancer treatment (such as chemotherapy, radiation, or surgery).
- You are 20 years old or older.
- You are able to understand and sign a consent form.
- You do not have any other active cancer besides pancreatic cancer.
- Your doctor expects you to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks tiny pieces of cancer DNA in your blood after pancreatic cancer surgery to see if they can predict whether cancer might come back. Researchers will draw blood several times over the next year to test this new monitoring approach.
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This study looks at DNA signals from blood tests (so-called “ctDNA” and another type of DNA test) in people with early-stage pancreatic cancer. It aims to see whether these tests can help track cancer after surgery and check for signs of return.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
Hear when a new MicroRNAs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.